by | Jan 13, 2025 | Lupus Foundation of America, News & Events
Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people with systemic lupus erythematosus (SLE) were found to be at higher risk for developing multiple cutaneous lupus erythematosus disease (CLE, lupus...
by | Jan 10, 2025 | Lupus Foundation of America, News & Events
IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) and IGM-2644 (an IgM-based CD38 X CD3 bispecific antibodyT cell...
by | Jan 10, 2025 | Lupus Foundation of America
January is Mental Wellness Month! We asked Heather Rose Artushin, a licensed clinical social worker, to share information and insights into understanding and protecting your mental health when you have lupus.This blog post is the first in a four-part series that we...
by | Jan 9, 2025 | Lupus Foundation of America, News & Events
In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their design with study populations and outcomes, examining the results and...
by | Jan 9, 2025 | Lupus Foundation of America
We understand the incredible stress, uncertainty and emotional distress that a natural disaster causes those affected by it. As wildfires continue to impact the Southern California region, we wanted to provide a list of resources and information for those who are...
by | Jan 8, 2025 | Lupus Foundation of America, News & Events
In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s multifaceted immunomodulatory properties target key aspects of SLE...
